Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial
International Journal of COPD2022Vol. Volume 17, pp. 2745–2755
Citations Over TimeTop 10% of 2022 papers
David Halpin, Robyn Kendall, Soham Shukla, Alan Martin, Dhvani Shah, Dawn Midwinter, Kai Michael Beeh, Janwillem Kocks, Paul Jones, Chris Compton, Nancy Risebrough, Afisi Ismaila
Abstract
Based on this analysis, in a UK setting, FF/UMEC/VI would improve health outcomes and reduce costs compared with non-ELLIPTA MITT for the treatment of patients with symptomatic COPD. SITT may help to reduce the clinical and economic burden of COPD and should be considered by physicians as a preferred treatment option.
Related Papers
- → Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma(1999)99 cited
- → Cost-Effectiveness Analysis of Salmeterol/Fluticasone Propionate 50/500??g vs Fluticasone Propionate 500??g in Patients with Corticosteroid-Dependent Asthma V: Results(1999)26 cited
- → Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease(2004)11 cited
- → Effects of fluticasone propionate and salmeterol hydrofluoroalkane inhalation aerosol on asthma-related quality of life(2009)4 cited
- → Fluticasone propionate/salmeterol (Wixela® Inhub®) dry-powder inhaler in asthma and COPD: a profile of its use in the USA(2019)